Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Claudia Nehring"'
Autor:
Georg-Nikolaus Franke, Konstantin Dumann, Madlen Jentzsch, Astrid Monecke, Christine Doehring, Claudia Nehring-Vucinic, Sebastian Schwind, Dietger Niederwieser, Uwe Platzbecker, Mirjana Ziemer, Vladan Vucinic
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Sezary Syndrome (SS) is a rare leukemic variant of primary cutaneous T-cell lymphoma. Relapsed or refractory disease is generally considered incurable by conventional therapeutic approaches, although durable responses can be achieved with novel monoc
Externí odkaz:
https://doaj.org/article/e0d8e0c4f55c440bb669798175424f67
Autor:
Thoralf Lange, Anja Edelmann, Udo Siebolts, Rainer Krahl, Claudia Nehring, Nadja Jäkel, Michael Cross, Jacqueline Maier, Dietger Niederwieser, Claudia Wickenhauser
Publikováno v:
Haematologica, Vol 98, Iss 5 (2013)
The risk profile and prognosis of patients with myelofibrosis is well described by the Dynamic International Prognostic Scoring System risk categorization. Allogeneic stem cell transplantation is considered for intermediate-2/high risk disease. Howev
Externí odkaz:
https://doaj.org/article/d877e4af67af4e2a88c24f6694acb97c
Autor:
Sebastian Schwind, Vladan Vucinic, Wolfram Pönisch, Runa Stiegler, Yvonne Remane, Claudia Nehring, Dietger Niederwieser, Michael Cross, Kristina Schakols, Constanze Kliem, Madlen Jentzsch, Sabine Leiblein
Publikováno v:
Blood. 132:2064-2064
Introduction: For allogeneic stem cell donation it is current practice to mobilize with G-CSF bid for 5 days. Here, the feasibility of mobilizing with a single injection of pegfiligrastim was examined in a phase II study with an emphasis on donor saf
Autor:
Rainer Krahl, Nadja Jäkel, Dietger Niederwieser, Claudia Nehring, Udo Siebolts, Jacqueline Maier, Anja Edelmann, Claudia Wickenhauser, Thoralf Lange, Michael Cross
The risk profile and prognosis of patients with myelofibrosis is well described by the Dynamic International Prognostic Scoring System risk categorization. Allogeneic stem cell transplantation is considered for intermediate-2/high risk disease. Howev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29c01c6f7efb05f61c29d6bb0806bca3
https://europepmc.org/articles/PMC3640116/
https://europepmc.org/articles/PMC3640116/
Autor:
Susann Schulze, Madlen Jentzsch, Nadja Jaekel, Song-Yau Wang, Simone Heyn, Sebastian Schwind, Wolfram Poenisch, Claudia Nehring, Yvonne Remane, Jan-Phillip Stümpel, Sabine Leiblein, Georg-Nikolaus Franke, Vladan Vucinic, Elena Ruschpler, Dietger Niederwieser
Publikováno v:
Blood. 126:5439-5439
Introduction: Up to 30% of patients (pts) undergoing stem cell mobilization with granulocyte colony-stimulating factor (G-CSF) with or without prior chemotherapy mobilize poorly. Plerixafor is a potent CXCR4 receptor antagonist that is licensed for s
Autor:
Nadja Jaekel, Cornelia Becker, Leanthe Braunert, Thoralf Lange, Rainer Krahl, Georg Franke, Dietger Niederwieser, Jeanett Edelmann, Wolfram Poenisch, Sabine Leiblein, Claudia Nehring, Haifa Kathrin Al-Ali
Publikováno v:
Blood. 118:3065-3065
Abstract 3065 Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity-conditioning (RIC) is a curative therapeutic option in elderly patients with AML. Yet, hematological relapse (HR) and non-relapse mortality (NRM) remain maj
Autor:
Michael Cross, Maier Jacqueline, Dietger Niederwieser, Thoralf Lange, Nadja Jäckel, Anja Edelmann, Uwe Siebolts, Claudia Wickenhauser, Claudia Nehring
Publikováno v:
Blood. 116:3462-3462
Abstract 3462 Detection of JAK2 p.V617F point mutation plays an important role in the initial diagnosis of myeloproliferative neoplasms (MPN) and also in the monitoring of JAK2 p.V617F positive MPN following allogeneic stem cell transplantation (SCT)
Autor:
Cornelia Becker, Wolfram Poenisch, Dietger Niederwieser, Haifa Kathrin Al-Ali, Rainer Krahl, Claudia Nehring, Jeanett Edelmann, Sabine Leiblein, Wolf-Dieter Kortmann, Thoralf Lange
Publikováno v:
Blood. 110:5033-5033
Introduction: Relapse of the malignant disease remains the major challenge after reduced intensity conditioning (RIC) HCT. Here we investigate the outcome of haematological relapse after low dose TBI-based conditioning regimens and the possibility to
Autor:
Haifa Kathrin Al-Ali, Sabine Leiblein, Rainer Krahl, Jeanett Edelmann, Wolfram Poenisch, Claudia Nehring, Dietger Niederwieser, Cornelia Becker, Thoralf Lange
Publikováno v:
Blood. 110:1654-1654
Relapse (RI) after HCT especially after RIC remains the major risk factor affecting outcome. Factors influencing relapse in patients (pts) with AML/MDS undergoing HCT after RIC were analysed. Patients and methods: From July, 1998- December, 2006, 156